(Q74650216)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Suramin treatment in hormone- and chemotherapy-refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

1 reference

1 reference

J M Garcia-Schürmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

H Schulze

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G Haupt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

J Pastor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

B Allolio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

T Senge

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

English

0 references

publication date

1 March 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

535-541

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Suramin in adrenocortical cancer: limited efficacy and serious toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

1 reference

7 January 2021

Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900544-5

7 January 2021

10.1016/S0090-4295(98)00544-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096380%20AND%20SRC:MED&resulttype=core&format=json